D. McDonald

Molecular Biology · American Journal of Pathology · 2000–2007

A researcher in the Science corpus: 13 papers; trusts 10 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 72 citations into it; #4,259 of 17,773 by trust here, #2,137 by citations
• Oncology — 43 citations into it; #1,179 of 1,698 by trust here, #450 by citations
• Cancer Research — 30 citations into it; #824 of 1,780 by trust here, #378 by citations
• Immunology and Allergy — 9 citations into it; #101 of 206 by trust here, #36 by citations

Whom D. McDonald trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Rakesh K. Jain
2. H. Hashizume
3. Ralph Weissleder
4. P. Baluk

Who trusts D. McDonald overall

1. D. Hanahan
2. Rakesh K. Jain
3. Dai Fukumura
4. Lisa M. Coussens
5. P. Baluk
6. Ralph Weissleder
7. D. Neri
8. Hisataka Kobayashi
9. W. Zipfel

Papers from D. McDonald's perspective

Ordered by how strongly the researchers D. McDonald trusts endorse each paper. Same corpus, a different order for every researcher.

1. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
2. Openings between defective endothelial cells explain tumor vessel leakiness. (American Journal of Pathology)
3. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
4. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (American Journal of Pathology)
5. Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
6. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. (American Journal of Pathology)
7. Pathology: Cancer cells compress intratumour vessels (Nature)
8. Imaging of angiogenesis: from microscope to clinic (Nature Medicine)
9. The biology of VEGF and its receptors (Nature Medicine)
10. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. (Cancer Cell)

Their papers

• Angiopoietin-1 protects the adult vasculature against plasma leakage (2000) — 1,353 citations
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. (2004) — 759 citations
• Openings between defective endothelial cells explain tumor vessel leakiness. (2000) — 1,654 citations
• Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. (2000) — 706 citations
• Rapid vascular regrowth in tumors after reversal of VEGF inhibition. (2006) — 832 citations
• Imaging of angiogenesis: from microscope to clinic (2003) — 1,067 citations
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. (2006) — 786 citations
• Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice (2001) — 691 citations
• Functionally specialized junctions between endothelial cells of lymphatic vessels (2007) — 958 citations
• Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007) — 992 citations
• Cellular abnormalities of blood vessels as targets in cancer. (2005) — 809 citations
• Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. (2005) — 618 citations
• Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. (2002) — 1,030 citations